{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:28:54Z","timestamp":1791869334422,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T00:00:00Z","timestamp":1512172800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_149493"],"award-info":[{"award-number":["320030_149493"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_170249"],"award-info":[{"award-number":["320030_170249"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00228-017-2392-2","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T07:15:36Z","timestamp":1512198936000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA"],"prefix":"10.1007","volume":"74","author":[{"given":"Patrick","family":"Vizeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette E.","family":"Meyer zu Schwabedissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,2]]},"reference":[{"issue":"11","key":"2392_CR1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, Liechti ME (2014) MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci 9(11):1645\u20131652. \nhttps:\/\/doi.org\/10.1093\/scan\/nst161","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"8","key":"2392_CR2","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/scan\/nsu035","volume":"9","author":"MC Wardle","year":"2014","unstructured":"Wardle MC, Kirkpatrick MG, de Wit H (2014) \u2018Ecstasy\u2019 as a social drug: MDMA preferentially affects responses to emotional stimuli with social content. Soc Cogn Affect Neurosci 9(8):1076\u20131081. \nhttps:\/\/doi.org\/10.1093\/scan\/nsu035","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"1","key":"2392_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 27(1):40\u201352. \nhttps:\/\/doi.org\/10.1177\/0269881112464827","journal-title":"J Psychopharmacol"},{"issue":"4","key":"2392_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2010","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome I, Doblin R (2010) The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25(4):439\u2013452. \nhttps:\/\/doi.org\/10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"issue":"11","key":"2392_CR5","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/j.1360-0443.2006.01566.x","volume":"101","author":"JG Ramaekers","year":"2006","unstructured":"Ramaekers JG, Kuypers KP, Samyn N (2006) Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction 101(11):1614\u20131621. \nhttps:\/\/doi.org\/10.1111\/j.1360-0443.2006.01566.x","journal-title":"Addiction"},{"issue":"5","key":"2392_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31(5):576\u2013588. \nhttps:\/\/doi.org\/10.1177\/0269881117691569","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2392_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/clpt.2011.78","volume":"90","author":"CM Hysek","year":"2011","unstructured":"Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\u201cecstasy\u201d) in humans. Clin Pharmacol Ther 90(2):246\u2013255. \nhttps:\/\/doi.org\/10.1038\/clpt.2011.78","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2392_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002130000648","volume":"154","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154(2):161\u2013168. \nhttps:\/\/doi.org\/10.1007\/s002130000648","journal-title":"Psychopharmacology"},{"issue":"3","key":"2392_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","volume":"27","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Schmid Y, Prestin K, Meyer zu Schwabedissen HE, Liechti ME (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharmacol 27(3):232\u2013238. \nhttps:\/\/doi.org\/10.1016\/j.euroneuro.2017.01.008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"2392_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FPC.0000000000000231","volume":"26","author":"Y Schmid","year":"2016","unstructured":"Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer zu Schwabedissen HE, Liechti ME (2016) CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of MDMA in a controlled study in healthy subjects. Pharmacogenet Genomics 26(8):397\u2013401. \nhttps:\/\/doi.org\/10.1097\/FPC.0000000000000231","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"2392_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/17470919.2016.1143026","volume":"11","author":"AK Bershad","year":"2016","unstructured":"Bershad AK, Weafer JJ, Kirkpatrick MG, Wardle MC, Miller MA, de Wit H (2016) Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc Neurosci 11(6):592\u2013599. \nhttps:\/\/doi.org\/10.1080\/17470919.2016.1143026","journal-title":"Soc Neurosci"},{"key":"2392_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fgene.2012.00235","volume":"3","author":"R Torre de la","year":"2012","unstructured":"de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farre M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relvant? Front Genet 3:235. \nhttps:\/\/doi.org\/10.3389\/fgene.2012.00235","journal-title":"Front Genet"},{"issue":"5","key":"2392_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Kr\u00e4henb\u00fchl S, Grouzmann E, Hoener MC, Liechti ME (2012) Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One 7(5):e36476. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0036476","journal-title":"PLoS One"},{"issue":"1","key":"2392_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32\u201341. \nhttps:\/\/doi.org\/10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","journal-title":"Synapse"},{"issue":"5","key":"2392_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","volume":"89","author":"G Rudnick","year":"1992","unstructured":"Rudnick G, Wall SC (1992) The molecular mechanism of \u201cecstasy\u201d [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89(5):1817\u20131821. \nhttps:\/\/doi.org\/10.1073\/pnas.89.5.1817","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2392_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","volume":"168","author":"L Simmler","year":"2013","unstructured":"Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener M, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168(2):458\u2013470. \nhttps:\/\/doi.org\/10.1111\/j.1476-5381.2012.02145.x","journal-title":"Br J Pharmacol"},{"issue":"4","key":"2392_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","volume":"189","author":"CD Verrico","year":"2007","unstructured":"Verrico CD, Miller GM, Madras BK (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4):489\u2013503. \nhttps:\/\/doi.org\/10.1007\/s00213-005-0174-5","journal-title":"Psychopharmacology"},{"issue":"3","key":"2392_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/026988110001400313","volume":"14","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (\u2018ecstasy\u2019) in healthy volunteers. J Psychopharmacol 14(3):269\u2013274. \nhttps:\/\/doi.org\/10.1177\/026988110001400313","journal-title":"J Psychopharmacol"},{"issue":"5","key":"2392_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/JCP.0b013e3182979d32","volume":"33","author":"CM Hysek","year":"2013","unstructured":"Hysek CM, Fink AE, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2013) Alpha-adrenergic receptors contribute to the acute effects of MDMA in humans. J Clin Psychopharmacol 33(5):658\u2013666. \nhttps:\/\/doi.org\/10.1097\/JCP.0b013e3182979d32","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"2392_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3109\/00952990903383961","volume":"35","author":"M Sofuoglu","year":"2009","unstructured":"Sofuoglu M, Poling J, Hill K, Kosten T (2009) Atomoxetine attenuates dextroamphetamine effects in humans. Am J Drug Alcohol Abuse 35(6):412\u2013416. \nhttps:\/\/doi.org\/10.3109\/00952990903383961","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"2392_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00213-012-2761-6","volume":"224","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Liechti ME (2012) Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex. Psychopharmacology 224(3):363\u2013376. \nhttps:\/\/doi.org\/10.1007\/s00213-012-2761-6","journal-title":"Psychopharmacology"},{"issue":"2","key":"2392_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/clpt.2011.125","volume":"90","author":"TF Newton","year":"2011","unstructured":"Newton TF (2011) A perhaps unexpected role of norepinephrine in actions of MDMA. Clin Pharmacol Ther 90(2):215\u2013216. \nhttps:\/\/doi.org\/10.1038\/clpt.2011.125","journal-title":"Clin Pharmacol Ther"},{"issue":"1-3","key":"2392_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.drugalcdep.2007.07.005","volume":"92","author":"WW Stoops","year":"2008","unstructured":"Stoops WW, Blackburn JW, Hudson DA, Hays LR, Rush CR (2008) Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. Drug Alcohol Depend 92(1-3):282\u2013285. \nhttps:\/\/doi.org\/10.1016\/j.drugalcdep.2007.07.005","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"2392_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1291\/hypres.26.685","volume":"26","author":"K Ono","year":"2003","unstructured":"Ono K, Iwanaga Y, Mannami T, Kokubo Y, Tomoike H, Komamura K, Shioji K, Yasui N, Tago N, Iwai N (2003) Epidemiological evidence of an association between SLC6A2 gene polymorphism and hypertension. Hypertens Res 26(9):685\u2013689. \nhttps:\/\/doi.org\/10.1291\/hypres.26.685","journal-title":"Hypertens Res"},{"issue":"5","key":"2392_CR25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1751-7176.2012.00618.x","volume":"14","author":"O Zolk","year":"2012","unstructured":"Zolk O, Ott C, Fromm MF, Schmieder RE (2012) Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians. J Clin Hypertens (Greenwich) 14(5):293\u2013298. \nhttps:\/\/doi.org\/10.1111\/j.1751-7176.2012.00618.x","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"2392_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00213-009-1628-y","volume":"206","author":"AM Dlugos","year":"2009","unstructured":"Dlugos AM, Hamidovic A, Palmer AA, de Wit H (2009) Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology 206(3):501\u2013511. \nhttps:\/\/doi.org\/10.1007\/s00213-009-1628-y","journal-title":"Psychopharmacology"},{"issue":"11","key":"2392_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.biopsych.2006.09.031","volume":"61","author":"A Dlugos","year":"2007","unstructured":"Dlugos A, Freitag C, Hohoff C, McDonald J, Cook EH, Deckert J, de Wit H (2007) Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry 61(11):1296\u20131305. \nhttps:\/\/doi.org\/10.1016\/j.biopsych.2006.09.031","journal-title":"Biol Psychiatry"},{"issue":"4","key":"2392_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/FPC.0b013e328344f63e","volume":"21","author":"U Kohli","year":"2011","unstructured":"Kohli U, Hahn MK, English BA, Sofowora GG, Muszkat M, Li C, Blakely RD, Stein CM, Kurnik D (2011) Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Pharmacogenet Genomics 21(4):171\u2013178. \nhttps:\/\/doi.org\/10.1097\/FPC.0b013e328344f63e","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"2392_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1601-183X.2007.00384.x","volume":"7","author":"MK Hahn","year":"2008","unstructured":"Hahn MK, Blackford JU, Haman K, Mazei-Robison M, English BA, Prasad HC, Steele A, Hazelwood L, Fentress HM, Myers R, Blakely RD, Sanders-Bush E, Shelton R (2008) Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression. Genes Brain Behav 7(4):487\u2013495. \nhttps:\/\/doi.org\/10.1111\/j.1601-183X.2007.00384.x","journal-title":"Genes Brain Behav"},{"issue":"9","key":"2392_CR30","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1176\/appi.ajp.161.9.1575","volume":"161","author":"K Yoshida","year":"2004","unstructured":"Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB (2004) Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 161(9):1575\u20131580. \nhttps:\/\/doi.org\/10.1176\/appi.ajp.161.9.1575","journal-title":"Am J Psychiatry"},{"issue":"1","key":"2392_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1369-1600.2010.00263.x","volume":"17","author":"TK Clarke","year":"2012","unstructured":"Clarke TK, Dempster E, Docherty SJ, Desrivieres S, Lourdsamy A, Wodarz N, Ridinger M, Maier W, Rietschel M, Schumann G (2012) Multiple polymorphisms in genes of the adrenergic stress system confer vulnerability to alcohol abuse. Addict Biol 17(1):202\u2013208. \nhttps:\/\/doi.org\/10.1111\/j.1369-1600.2010.00263.x","journal-title":"Addict Biol"},{"issue":"2","key":"2392_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1124\/jpet.111.188425","volume":"340","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M, Grouzmann E, Hoener MC, Liechti ME (2012) Effects of the alpha2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340(2):286\u2013294. \nhttps:\/\/doi.org\/10.1124\/jpet.111.188425","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2392_CR33","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/j.1476-5381.2012.01936.x","volume":"166","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Schmid Y, Rickli A, Simmler LD, Donzelli M, Grouzmann E, Liechti ME (2012) Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol 166(8):2277\u20132288. \nhttps:\/\/doi.org\/10.1111\/j.1476-5381.2012.01936.x","journal-title":"Br J Pharmacol"},{"issue":"03","key":"2392_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1017\/S1461145713001132","volume":"17","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, Liechti ME (2014) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone and in combination. Int J Neuropsychopharmacol 17(03):371\u2013381. \nhttps:\/\/doi.org\/10.1017\/S1461145713001132","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"2392_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/jpet.114.222356","volume":"353","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Rickli A, Schaffner A, Duthaler U, Grouzmann E, Hysek CM, Liechti ME (2015) Interactions between bupropion and 3,4-methylenedioxymethamphetamine in healthy subjects. J Pharmacol Exp Ther 353(1):102\u2013111. \nhttps:\/\/doi.org\/10.1124\/jpet.114.222356","journal-title":"J Pharmacol Exp Ther"},{"key":"2392_CR36","doi-asserted-by":"publisher","unstructured":"Dolder PC, Muller F, Schmid Y, Borgwardt SJ, Liechti ME (2017) Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology (in press). \nhttps:\/\/doi.org\/10.1007\/s00213-017-4650-5","DOI":"10.1007\/s00213-017-4650-5"},{"issue":"4","key":"2392_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00213-011-2529-4","volume":"220","author":"TM Brunt","year":"2012","unstructured":"Brunt TM, Koeter MW, Niesink RJ, van den Brink W (2012) Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology 220(4):751\u2013762. \nhttps:\/\/doi.org\/10.1007\/s00213-011-2529-4","journal-title":"Psychopharmacology"},{"issue":"7","key":"2392_CR38","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1021\/ac4004584","volume":"85","author":"M Dunand","year":"2013","unstructured":"Dunand M, Gubian D, Stauffer M, Abid KA, Grouzmann E (2013) High throughput and sensitive quantitation of plasma catecholamines by ultraperformance liquid chromatography-tandem mass spectrometry using a solid phase microwell extraction plate. Anal Chem 85(7):3539\u20133544. \nhttps:\/\/doi.org\/10.1021\/ac4004584","journal-title":"Anal Chem"},{"issue":"5","key":"2392_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/npp.2012.245","volume":"38","author":"AB Hart","year":"2013","unstructured":"Hart AB, de Wit H, Palmer AA (2013) Candidate gene studies of a promising intermediate phenotype: failure to replicate. Neuropsychopharmacology 38(5):802\u2013816. \nhttps:\/\/doi.org\/10.1038\/npp.2012.245","journal-title":"Neuropsychopharmacology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-017-2392-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T00:38:49Z","timestamp":1518223129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-017-2392-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,2]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["2392"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2392-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,2]]}}}